| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGaV |
| Uniprot No | P06756 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1048aa |
| 氨基酸序列 | MAFPPRRRLR LGPRGLPLLL SGLLLPLCRA FNLDVDSPAE YSGPEGSYFG FAVDFFVPSA SSRMFLLVGA PKANTTQPGI VEGGQVLKCD WSSTRRCQPI EFDATGNRDY AKDDPLEFKS HQWFGASVRS KQDKILACAP LYHWRTEMKQ EREPVGTCFL QDGTKTVEYA PCRSQDIDAD GQGFCQGGFS IDFTKADRVL LGGPGSFYWQ GQLISDQVAE IVSKYDPNVY SIKYNNQLAT RTAQAIFDDS YLGYSVAVGD FNGDGIDDFV SGVPRAARTL GMVYIYDGKN MSSLYNFTGE QMAAYFGFSV AATDINGDDY ADVFIGAPLF MDRGSDGKLQ EVGQVSVSLQ RASGDFQTTK LNGFEVFARF GSAIAPLGDL DQDGFNDIAI AAPYGGEDKK GIVYIFNGRS TGLNAVPSQI LEGQWAARSM PPSFGYSMKG ATDIDKNGYP DLIVGAFGVD RAILYRARPV ITVNAGLEVY PSILNQDNKT CSLPGTALKV SCFNVRFCLK ADGKGVLPRK LNFQVELLLD KLKQKGAIRR ALFLYSRSPS HSKNMTISRG GLMQCEELIA YLRDESEFRD KLTPITIFME YRLDYRTAAD TTGLQPILNQ FTPANISRQA HILLDCGEDN VCKPKLEVSV DSDQKKIYIG DDNPLTLIVK AQNQGEGAYE AELIVSIPLQ ADFIGVVRNN EALARLSCAF KTENQTRQVV CDLGNPMKAG TQLLAGLRFS VHQQSEMDTS VKFDLQIQSS NLFDKVSPVV SHKVDLAVLA AVEIRGVSSP DHVFLPIPNW EHKENPETEE DVGPVVQHIY ELRNNGPSSF SKAMLHLQWP YKYNNNTLLY ILHYDIDGPM NCTSDMEINP LRIKISSLQT TEKNDTVAGQ GERDHLITKR DLALSEGDIH TLGCGVAQCL KIVCQVGRLD RGKSAILYVK SLLWTETFMN KENQNHSYSL KSSASFNVIE FPYKNLPIED ITNSTLVTTN VTWGIQPAPM PVPVWVIILA VLAGLLLLAV LVFVMYRMGF FKRVRPPQEE QEREQLQPHE NGEGNSET |
| 预测分子量 | 143 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGaV重组蛋白的3条参考文献示例(注：以下内容为模拟生成，实际文献需通过学术数据库验证)：
1. **文献名称**: "Functional characterization of recombinant integrin αV subunit in cell adhesion mechanisms"
**作者**: Smith A, et al.
**摘要**: 研究通过表达并纯化重组ITGaV蛋白，验证其与胞外基质蛋白(如纤连蛋白和玻连蛋白)的相互作用，揭示其在细胞粘附和迁移中的关键调控作用。
2. **文献名称**: "Targeting recombinant ITGaV for anti-angiogenic therapy in tumor models"
**作者**: Chen L, et al.
**摘要**: 利用重组ITGaV蛋白阻断肿瘤血管内皮细胞中整合素αVβ3/β5信号通路，显著抑制小鼠模型中肿瘤血管生成和转移。
3. **文献名称**: "Structural insights into recombinant ITGaV/β6 integrin complex"
**作者**: Tanaka K, et al.
**摘要**: 通过冷冻电镜解析重组ITGaV与β6亚基复合物的三维结构，阐明其与TGF-β激活相关的分子机制，为纤维化疾病治疗提供新靶点。
4. **文献名称**: "Recombinant ITGaV-based nanoparticles for targeted drug delivery"
**作者**: Wang Y, et al.
**摘要**: 开发基于重组ITGaV蛋白的纳米颗粒载体，利用其RGD结构域特异性靶向肿瘤细胞，提高化疗药物的递送效率并减少脱靶毒性。
**建议**：可通过PubMed、Web of Science等平台检索关键词“recombinant ITGaV/integrin alpha V”获取真实文献。
ITGaV (Integrin Alpha V) is a key subunit of the integrin family, a group of cell surface receptors that mediate cell-cell and cell-extracellular matrix (ECM) interactions. Integrins are heterodimeric proteins composed of α and β subunits. ITGaV pairs primarily with β subunits (e.g., β1. β3. β5. β6. β8) to form distinct integrins such as αVβ3. αVβ5. and αVβ6. These complexes bind to ECM proteins containing the Arg-Gly-Asp (RGD) motif, including fibronectin, vitronectin, and osteopontin, facilitating cellular processes like adhesion, migration, proliferation, and survival.
Recombinant ITGaV proteins are engineered in vitro using expression systems (e.g., mammalian, insect cells) to ensure proper post-translational modifications and functional activity. These proteins retain critical domains, such as the ligand-binding β-propeller domain, enabling studies on integrin-mediated signaling and adhesion mechanisms. ITGaV is implicated in pathological conditions, including cancer metastasis, angiogenesis, fibrosis, and inflammatory diseases, making its recombinant form a valuable tool for drug discovery and mechanistic research. For example, αVβ3 and αVβ5 are targets for anticancer therapies due to their roles in tumor vasculature. Recombinant ITGaV also aids in developing RGD-based inhibitors or antibodies to modulate integrin functions.
Research applications include in vitro binding assays, cell adhesion studies, and screening therapeutic compounds. Its role in viral entry (e.g., foot-and-mouth disease virus) further underscores its biomedical relevance. By providing a purified, bioactive form, recombinant ITGaV accelerates understanding of integrin biology and therapeutic targeting.
×
